Literature DB >> 19368984

Improvement in tumour control probability with active breathing control and dose escalation: a modelling study.

Mike Partridge1, Alison Tree, Juliet Brock, Helen McNair, Elizabeth Fernandez, Niki Panakis, Michael Brada.   

Abstract

INTRODUCTION: The prognosis from non-small cell lung cancer remains poor, even in those patients suitable for radical radiotherapy. The ability of radiotherapy to achieve local control is hampered by the sensitivity of normal structures to irradiation at the high tumour doses needed. This study aimed to look at the potential gain in tumour control probability from dose escalation facilitated by moderate deep inspiration breath-hold.
METHOD: The data from 28 patients, recruited into two separate studies were used. These patients underwent planning with and without the use of moderate deep inspiration breath-hold with an active breathing control (ABC) device. Whilst maintaining the mean lung dose (MLD) at the level of the conventional plan, the ABC plan dose was theoretically escalated to a maximum of 84 Gy, constrained by usual normal tissue tolerances. Calculations were performed using data for both lungs and for the ipsilateral lung only. Resulting local progression-free survival at 30 months was calculated using a standard logistic model.
RESULTS: The prescription dose could be escalated from 64 Gy to a mean of 73.7+/-6.5 Gy without margin reduction, which represents a statistically significant increase in tumour control probability from 0.15+/-0.01 to 0.29+/-0.11 (p<0.0001). The results were not statistically different whether both lungs or just the ipsilateral lung was used for calculations.
CONCLUSION: A near-doubling of tumour control probability is possible with modest dose escalation, which can be achieved with no extra increase in lung dose if deep inspiration breath-hold techniques are used.

Entities:  

Mesh:

Year:  2009        PMID: 19368984     DOI: 10.1016/j.radonc.2009.03.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  8 in total

1.  [Image-guided radiation therapy].

Authors:  J Boda-Heggemann; M Guckenberger; U Ganswindt; C Belka; H Wertz; M Blessing; F Wenz; M Fuss; F Lohr
Journal:  Radiologe       Date:  2012-03       Impact factor: 0.635

Review 2.  kV cone-beam CT-based IGRT: a clinical review.

Authors:  Judit Boda-Heggemann; Frank Lohr; Frederik Wenz; Michael Flentje; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2011-04-26       Impact factor: 3.621

Review 3.  Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy?

Authors:  Anna O Simeonova; Katharina Fleckenstein; Hansjörg Wertz; Anian Frauenfeld; Judit Boda-Heggemann; Frank Lohr; Frederik Wenz
Journal:  Transl Lung Cancer Res       Date:  2012-03

4.  Automatically gated image-guided breath-hold IMRT is a fast, precise, and dosimetrically robust treatment for lung cancer patients.

Authors:  Anna Simeonova-Chergou; Anika Jahnke; Kerstin Siebenlist; Florian Stieler; Sabine Mai; Judit Boda-Heggemann; Frederik Wenz; Frank Lohr; Lennart Jahnke
Journal:  Strahlenther Onkol       Date:  2016-01-15       Impact factor: 3.621

5.  An offline technique to evaluate residual motion of the diaphragm during deep inspiratory breath-hold from cone-beam CT datasets.

Authors:  Manuel Blessing; Julian Hofmann; Lena Vogel; Judit Boda-Heggemann; Frank Lohr; Frederik Wenz; Florian Stieler; Anna Simeonova-Chergou
Journal:  Strahlenther Onkol       Date:  2018-05-22       Impact factor: 3.621

6.  Fidelity of dose delivery at high dose rate of volumetric modulated arc therapy in a truebeam linac with flattening filter free beams.

Authors:  Georgios Kalantzis; Jianguo Qian; Bin Han; Gary Luxton
Journal:  J Med Phys       Date:  2012-10

Review 7.  [Advances of precise radiotherapy for lung cancer].

Authors:  Xin Wang; Feng Xu; Yuquan Wei
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-11

8.  A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer.

Authors:  Chenxue Jiang; Shuiyun Han; Wucheng Chen; Xiaozhen Ying; He Wu; Yaoyao Zhu; Guodong Shi; Xiaojiang Sun; Yaping Xu
Journal:  Oncotarget       Date:  2018-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.